TXN and rheumatoid arthritis: The rheumatic drug KE-298 (2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid) influenced the secretion of Trx and increased the level of intracellular glutathione in human monocytes and T cells, thereby acting efficiently in the treatment of RA [169].